• Trifluoperazine 2HCl: Translational D2 Research

  2026-08-14

  A strategic guide to using Trifluoperazine 2HCl as a mechanistic anchor for dopamine receptor signaling, neuropharmacology, immune, and cancer research while separating receptor evidence from broader translational hypotheses.

• Iptacopan (LNP023) Workflows for Complement Research

  2026-08-13

  Build selective alternative-pathway experiments around Iptacopan (LNP023), from factor B enzyme testing to serum MAC formation, C3 deposition, and hemolysis. This workflow emphasizes quantitative concentration-response analysis, donor and species controls, and translational interpretation for complement-mediated disease models.

• Disodium Bicinchoninate in HUVEC Assay Workflows

  2026-08-13

  Disodium bicinchoninate brings a water-compatible chelating scaffold to protein-normalization, assay-development, and endothelial cell research workflows. This guide connects its handling advantages with the H2O2-induced HUVEC model used to study salidroside, inflammation, autophagy, and EZH2 regulation.

• Angiotensin (1-7): From RAS Biology to Assay Design

  2026-08-12

  Angiotensin (1-7) connects Mas receptor biology with fibrosis, inflammation, metabolism, and emerging spike-protein binding assays. This guide shows how peptide identity, pathway context, and assay architecture determine defensible conclusions.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflow

  2026-08-12

  Separate mRNA uptake from productive translation with a single dual-fluorescence reagent. EZ Cap™ Cy5 EGFP mRNA (5-moUTP) supports quantitative nanoparticle screening, macrophage delivery studies, and real-time optimization of intracellular trafficking.

• Angiotensin 1/2 (2-7) Research Workflow

  2026-08-11

  Build reproducible cardiovascular and receptor-binding assays with a defined Angiotensin 1/2 (2-7) peptide workflow. This guide connects blood pressure regulation research with a carefully bounded antiviral assay application while emphasizing controls, formulation, and interpretation.

• Novobiocin Workflows for Antiviral Research

  2026-08-10

  Novobiocin is an aminocoumarin antibiotic that supports coordinated antibacterial, antiparasitic, and antiviral assay development. This guide translates its reported activity against SFTSV, resistant staphylococci, and protozoan pathogens into practical dose-response, imaging, combination, and troubleshooting workflows.

• ICAA Targets RIP3 in Cardiac Hypertrophy

  2026-08-09

  A 2026 Cellular Signalling study identifies isochlorogenic acid A as a protective agent against angiotensin II- and pressure overload-induced cardiac hypertrophy. Its central advance is the definition of a RIP3/CaMKII mechanism that operates independently of MLKL, positioning RIP3 as a potential target for cardiovascular disease research.

• STING agonist-1: B Cell and TLS Research

  2026-08-08

  Build controlled STING activation assays that connect type I interferon biology with IRF4-driven B-cell responses and tertiary lymphoid structure research. This workflow uses DMSO-soluble STING agonist-1 for time-resolved stimulation, orthogonal pathway readouts, and mechanism-focused troubleshooting in immunology and cancer models.

• Ordered DNA Frameworks Improve Enzymatic Synthesis

  2026-08-07

  The reference study introduces tetrahedral DNA nanostructures as an ordered interface for improving enzyme access to primers during enzymatic oligonucleotide synthesis. This architecture reduced deletion errors and enabled a 60-nucleotide information-storage fragment with a reported stepwise yield of 96.82%, while also clarifying how nanoscale primer organization can influence synthesis performance.

• HDAC8 Drives AKT-Mediated Resistance to MEK1/2 Inhibition in

  2026-08-07

  This study uncovers how HDAC8 activity enables cancer cells to resist MEK1/2 inhibition by upregulating PLCB1 and suppressing DESC1, resulting in compensatory AKT activation. These insights highlight new molecular targets to overcome resistance in therapies targeting the MAPK/ERK pathway.

• Evaluating Fumagillin’s Efficacy Against Azumiobodo hoyamush

  2026-08-06

  This study systematically investigated the in vitro and in vivo efficacy of various antiprotozoal agents, including Fumagillin, against Azumiobodo hoyamushi—the causative agent of soft tunic syndrome in Halocynthia roretzi. Findings highlight Fumagillin’s moderate antiparasitic activity and inform future strategies for disease management in aquaculture and related research domains.

• Metoprolol Tartrate: Precision β1 Blockade in Cardiovascular

  2026-08-06

  Metoprolol Tartrate empowers researchers to selectively investigate β1-adrenergic signaling, enabling precise modeling of cardiovascular and hematopoietic phenomena. Its high selectivity and solubility profile from APExBIO make it a trusted tool in complex experimental workflows.

• Recombinant Human IL-15: Advanced Insights for Neuroimmune A

  2026-08-05

  Explore how Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) drives high-fidelity neuroimmune research and immune cell activation. This article delivers deeper mechanistic analysis and practical assay guidance beyond standard protocols.

• EdU Flow Cytometry Assay Kits (Cy3): Precision in Cell Cycle

  2026-08-05

  Discover how EdU Flow Cytometry Assay Kits (Cy3) enable nuanced cell cycle analysis and advanced drug sensitivity profiling—offering unique insights beyond standard proliferation assays. Unpack the scientific mechanisms, protocol strategies, and translational relevance for oncology research.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page